OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
RPH57

Ratchaphruek Hospital PCL

Healthcare Facilities & ServicesVerified

Ratchaphruek Hospital PCL maintains a strong liquidity position with a current ratio of 3.63, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity is further supported by a debt-to-equity ratio of 0.0, suggesting minimal reliance on debt financing. However, the company has a negative net cash position after subtracting total debt, which introduces some liquidity risk. In terms of profitability, the company's return on equity (ROE) of 10.63% and return on assets (ROA) of 9.56% are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and total assets. The operating margin, calculated as operating income of 231.54 million THB on revenue of 1.16 billion THB, is 19.92%, which is a healthy margin for a healthcare services provider. The company's revenue is concentrated in a single geographic location, Thailand, and it operates under a single business segment, the hospital business. This lack of diversification may expose the company to regional economic and regulatory risks. The company does not disclose revenue by geographic region or business segment beyond its primary hospital operations, limiting visibility into potential diversification opportunities. Looking ahead, the company's revenue is expected to grow, supported by its strong operating cash flow of 248.81 million THB and a free cash flow of 28.06 million THB. The capital expenditure of -84.99 million THB indicates the company is investing in its operations, which could support future growth. The company's outlook for the current fiscal year is positive, with expected growth in revenue and profitability. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The primary liquidity risk stems from the negative net cash position after subtracting total debt, which could affect the company's ability to meet short-term obligations. The low dilution risk is supported by the absence of significant dilution sources in the recent filings and the fact that shares outstanding have not changed between basic and diluted counts. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest financial statements show consistent performance, with no significant one-time events or accounting adjustments reported. The company's capital structure remains stable, with a low level of long-term debt and a strong equity base.

30-day price · RPH-0.02 (-0.4%)
Low$4.82High$5.05Close$4.88As of15 May, 00:00 UTC
Profile
CompanyRatchaphruek Hospital PCL
TickerRPH.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Ratchaphruek Hospital PCL operates a hospital business in Thailand, providing a range of medical services including stroke care, cardiology, orthopedics, and obstetrics and gynecology.

Classification. Ratchaphruek Hospital PCL is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Ratchaphruek Hospital PCL maintains a strong liquidity position with a current ratio of 3.63, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity is further supported by a debt-to-equity ratio of 0.0, suggesting minimal reliance on debt financing. However, the company has a negative net cash position after subtracting total debt, which introduces some liquidity risk. In terms of profitability, the company's return on equity (ROE) of 10.63% and return on assets (ROA) of 9.56% are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and total assets. The operating margin, calculated as operating income of 231.54 million THB on revenue of 1.16 billion THB, is 19.92%, which is a healthy margin for a healthcare services provider. The company's revenue is concentrated in a single geographic location, Thailand, and it operates under a single business segment, the hospital business. This lack of diversification may expose the company to regional economic and regulatory risks. The company does not disclose revenue by geographic region or business segment beyond its primary hospital operations, limiting visibility into potential diversification opportunities. Looking ahead, the company's revenue is expected to grow, supported by its strong operating cash flow of 248.81 million THB and a free cash flow of 28.06 million THB. The capital expenditure of -84.99 million THB indicates the company is investing in its operations, which could support future growth. The company's outlook for the current fiscal year is positive, with expected growth in revenue and profitability. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The primary liquidity risk stems from the negative net cash position after subtracting total debt, which could affect the company's ability to meet short-term obligations. The low dilution risk is supported by the absence of significant dilution sources in the recent filings and the fact that shares outstanding have not changed between basic and diluted counts. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest financial statements show consistent performance, with no significant one-time events or accounting adjustments reported. The company's capital structure remains stable, with a low level of long-term debt and a strong equity base.
Key takeaways
  • Ratchaphruek Hospital PCL has a strong liquidity position with a current ratio of 3.63 and a debt-to-equity ratio of 0.0.
  • The company generates solid returns with a return on equity of 10.63% and a return on assets of 9.56%.
  • Revenue is concentrated in a single geographic location and business segment, which may increase exposure to regional risks.
  • The company is investing in its operations with a capital expenditure of -84.99 million THB, supporting future growth.
  • The company has medium liquidity risk due to a negative net cash position after subtracting total debt.
  • The company has low dilution risk, with no significant dilution sources identified in recent filings.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$1.16B
Gross profit$390.5M
Operating income$231.5M
Net income$182.4M
R&D
SG&A
D&A
SBC
Operating cash flow$248.8M
CapEx-$85.0M
Free cash flow$28.1M
Total assets$1.91B
Total liabilities$193.1M
Total equity$1.72B
Cash & equivalents
Long-term debt$3.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.72B
Net cash-$3.3M
Current ratio3.6
Debt/Equity0.0
ROA9.6%
ROE10.6%
Cash conversion1.4%
CapEx/Revenue-7.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricRPHActivity
Op margin19.9%18.2% medp25 18.2% · p75 24.6%above median
Net margin15.7%14.7% medp25 11.7% · p75 28.1%above median
Gross margin33.6%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-7.3%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity0.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 08:13 UTC#f9099d74
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 08:16 UTCJob: aa464c89